BCR

About

Location: 22q11.23

Mappings

HGNC: HGNC:1014

Ensembl: ENSG00000186716

NCBI: 613

Refseq: NM_004327.4

Biomarkers

BCR is involved in the following curated biomarkers.

Name Biomarker type Propositions Statements
BCR::ABL1 Rearrangement 14 27
BCR::ABL1 Rearrangement 15 32

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
Sensitivity (+) ABL1 p.T315I, BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Imatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Imatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Cytarabine, Methotrexate, Ponatinib, Prednisone, Vincristine
Sensitivity (+) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
Sensitivity (+) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Asciminib
Sensitivity (+) BCR::ABL1, CD22 + Acute Lymphoid Leukemia Inotuzumab ozogamicin
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
Sensitivity (+) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
Sensitivity (+) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
Sensitivity (+) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
Sensitivity (+) BCR::ABL1, CD22 + Acute Lymphoid Leukemia Inotuzumab ozogamicin
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
Sensitivity (+) BCR::ABL1 Acute Lymphoid Leukemia Blinatumomab